Invasive Breast Cancer Clinical Trial
Official title:
Evaluation of the RESTART Survival Programme
Verified date | January 2024 |
Source | Jules Bordet Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | December 2026 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Age >= 18 at the time of signing the ICF 2. Minimum understanding of French 3. Signed study informed consent form obtained prior to any study-related procedure. 4. Participation in the RESTART programme 5. Patient with curative breast cancer (AJCC stage I-II-III) Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jules Bordet Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions. | To assess the global satisfaction with participation in the Restart programme and its various components via the Likert Scale. | 1 month after end of programme and 12 months after end of the programme | |
Secondary | assessment of quality of life | To measure changes in quality of life via EORTC30 questionnaire | baseline - 1 month after end of programme - 12 months after end of programme | |
Secondary | assessemnt of health literacy via HLQ questionnaire | to mesure changes in health literacy via HLQ questionnaire | baseline - 1 month after end of programme - 12 months after end of programme | |
Secondary | assessment of professional status | to assess the number of patients who return to work via open question | baseline - 1 month after end of programme- 12 months after end of programme | |
Secondary | assessment of level of physical activity | to measure the changes in level of physical activity via the Global Physical Activity Questionnaire (GPAQ) | baseline - 1 month after end of programme- 12 months after end of programme | |
Secondary | assessment of emotionnal distress | to measure the changes in emotional distress via questionnaire "generalized Anxiety Disorder" (GAD-7) | baseline - 1 month after end of programme- 12 months after end of programme | |
Secondary | assessment of the intensity of residual fatigue | to measure the intensity of residual fatigue via NRS (0= no fatigue and 10 = worst fatigue) | baseline - 1 month after end of programme- 12 months after end of programme | |
Secondary | assessment of sleep quality | changes in sleep quality via Pittsburgh sleep Quality index (PSQI) before and after participation in the RESTART programme. | baseline - 1 month after end of programme - 12 months after end of programme | |
Secondary | Measuring the rate of participation in the programme | Measure the participation rate in the program via the proportion of patients who participated compared to the number of patients operated on for breast cancer located in Bordet during the same period. | baseline - 1 month after end of programme - 12 months after end of programme | |
Secondary | assessment of quality of life | To measure changes in quality of life via BR 23 questionnaire | baseline - 1 month after end of programme - 12 months after end of programme | |
Secondary | assessment of emotionnal distress | to measure the changes in emotional distress via questionnaire "Patient Health Questionnaire-9" (PHQ-9) | baseline - 1 month after end of programme- 12 months after end of programme |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03595592 -
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT06158217 -
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
|
||
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT02773784 -
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
|
||
Recruiting |
NCT01509781 -
Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study
|
Phase 3 | |
Completed |
NCT04478669 -
Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
|
||
Recruiting |
NCT04553770 -
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04677816 -
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
|
Phase 2 | |
Terminated |
NCT01934335 -
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
|
Phase 2 | |
Completed |
NCT00507611 -
Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients
|
N/A | |
Completed |
NCT00581750 -
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
|
||
Completed |
NCT03304171 -
Overall Diet Quality and Breast Cancer Risk
|
N/A | |
Completed |
NCT03709186 -
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
|
||
Terminated |
NCT03361800 -
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
|
Early Phase 1 | |
Recruiting |
NCT04648904 -
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT06328465 -
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
|
N/A | |
Active, not recruiting |
NCT03109522 -
Axillary Reverse Mapping (ARM) Technique
|
N/A | |
Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
Recruiting |
NCT03497702 -
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
|
Phase 2 |